Terms: = Lung cancer AND MAP2K4, MEK4, 6416, P45985, ENSG00000065559, SERK1, JNKK1, MKK4, PRKMK4, MAPKK4, JNKK, SEK1 AND Prognosis
3 results:
1. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell lung cancer in Sweden.
Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
[TBL] [Abstract] [Full Text] [Related]
2. Analysis of survival of patients with metastatic malignant pleural mesothelioma.
Billè A; Okiror L; Harling L; Pernazza F; Muzio A; Roveta A; Grosso F
Tumori; 2021 Apr; 107(2):110-118. PubMed ID: 32458750
[TBL] [Abstract] [Full Text] [Related]
3. Epidemiology and diagnosis of pulmonary embolism in lung cancer patients: is there a role for age adjusted D-dimers cutoff?
Anagnostopoulos I; Lagou S; Spanorriga MK; Tavernaraki K; Poulakou G; Syrigos KN; Thanos L
J Thromb Thrombolysis; 2020 May; 49(4):572-577. PubMed ID: 31786713
[TBL] [Abstract] [Full Text] [Related]
